Schizophrenia Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Companies - Otsuka, Boehringer Ingelheim, Merck, Sunivion, PsychoGenics, Neurocrine Biosciences, Takeda, Lyndra, Cerevel
17 oct. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Schizophrenia Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Companies - Otsuka, Boehringer Ingelheim,...
The Future of Global Mental Health Management Research Report 2023: Complementing Prescription Therapies with AI/ML/VR for Better Outcomes to Become More Prominent
20 juil. 2023 05h38 HE
|
Research and Markets
Dublin, July 20, 2023 (GLOBE NEWSWIRE) -- The "The Future of Mental Health Management" report has been added to ResearchAndMarkets.com's offering. This report identifies the challenges, drivers,...
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
28 juin 2023 08h30 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Schizophrenia Drugs Market Size to Witness Healthy Valuation of US$ 12.6 Billion at 5.6% CAGR by 2032 | Market.us Report
25 mai 2023 07h54 HE
|
Market.Us
New York, May 25, 2023 (GLOBE NEWSWIRE) -- As per this latest study by Market.us, The global Schizophrenia Drugs Market was valued at US$ 7.4 Bn in 2022. It is projected to expand at a CAGR of 5.6%...
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
15 mai 2023 07h30 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
10 mai 2023 08h00 HE
|
Minerva Neurosciences, Inc
FDA confirms acceptance of the filing of the NDA for roluperidone Application has been granted a standard review FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 26,...
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
08 mai 2023 08h30 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
01 mai 2023 07h00 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Global Precision Psychiatry Market Report to 2027 - Increasing Adoption of Inorganic Growth Strategies and Increased Demand for Genomics as Precision Psychiatry Drives Growth
23 mars 2023 05h08 HE
|
Research and Markets
Dublin, March 23, 2023 (GLOBE NEWSWIRE) -- The "Precision Psychiatry Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Biomarkers (Genetic v/s Protein),...
Global Behavioural Health Treatment Market is expected to witness a CAGR of 2.9% during the forecast period of 2022 to 2032 | Fact.MR Report
21 mars 2023 10h00 HE
|
FACT.MR
Rockville, March 21, 2023 (GLOBE NEWSWIRE) -- The market for Behavioural Health Treatments will expand at a CAGR of 2.9%, over the forecasted time. The rise of telepsychiatry procedures in the...